Labcorp Holdings Inc (NYSE:LH) is reportedly collaborating with U.S. health regulators to determine whether it should scale up its mpox testing capabilities, following global concerns over a newly detected virus strain outside Africa.
According to Marcia Eisenberg, the company's chief scientific officer, Labcorp currently processes around 500 mpox tests monthly but can ramp up to 25,000 if necessary, Reuters noted, citing an emailed statement.
Also Read: Mpox Vaccine Maker Bavarian Nordic Targets Broader Access With European Submission For Imvanex Adolescent Use During WHO Emergency.
The company recently received U.S. clearance for a home collection kit that doctors can order for patients aged 18 and older who are suspected ...
